Verifying the markers of ovarian cancer using RNA‑seq data

Liu,Tianfeng; Yu,Nina; Ding,Feng; Wang,Surong; Li,Shihong; Zhang,Xiaofei; Sun,Xiangxiu; Chen,Ying; Liu,Peishu

doi:10.3892/mmr.2015.3489

Verifying the markers of ovarian cancer using RNA‑seq data

Authors:
- Tianfeng Liu
- Nina Yu
- Feng Ding
- Surong Wang
- Shihong Li
- Xiaofei Zhang
- Xiangxiu Sun
- Ying Chen
- Peishu Liu
View Affiliations

Affiliations: Department of Gynecology, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China, Department of Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong 250000, P.R. China
Published online on: March 13, 2015 https://doi.org/10.3892/mmr.2015.3489
Pages: 1125-1130

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Markers associated with diagnosis, presentation and potential therapeutic targets have received widespread attention in ovarian cancer research in the past few years. However, the majority of these markers have been investigated individually, and the changes in expression and the association between them are rarely documented. Next‑generation sequencing, also termed RNA‑seq when the sequencing targets are cDNAs, can provide a whole blueprint of the transcriptome of a specific tissue. In the present study, RNA‑seq data of human ovarian cancer samples were used to verify the expression of known markers and to identify the association between them. A total of 563 markers associated with ovarian cancer were retrieved from the database of the National Center of Biotechnology Information, and used as the target markers. The transcriptome of the ovarian tissue of four different tumors, containing tumor presentation and recurrence stages, were sequenced using the Illumina GAII platform. Approximately 85.97% markers were expressed of the total 563 markers, and the majority of them were involved in pathways associated with cancer, signaling and infection. In total, 85 markers were found to be aberrantly expressed in tumor cells from patients with ovarian cancer who had recurrences, including 33 upregulated markers at the recurrence stage. Therefore, they may have roles ovarian tumor due to their aberrant expression. Differentially expressed markers and the associations between them can be assessed by examining the RNA‑seq data. These findings may provide novel information for further studies on ovarian cancer.

View Figures

View References

1	Moss EL, Hollingworth J and Reynolds TM: The role of CA125 in clinical practice. J Clin Pathol. 58:308–312. 2005. View Article : Google Scholar : PubMed/NCBI
2	Lakhani SR, Manek S, Penault-Llorca F, et al: Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res. 10:2473–2481. 2004. View Article : Google Scholar : PubMed/NCBI
3	Rafnar T, Gudbjartsson DF, Sulem P, et al: Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet. 43:1104–1107. 2011. View Article : Google Scholar : PubMed/NCBI
4	Ducros E, Mirshahi S, Azzazene D, et al: Endothelial protein C receptor expressed by ovarian cancer cells as a possible biomarker of cancer onset. Int J Oncol. 41:433–440. 2012.PubMed/NCBI
5	Fung FK, Chan DW, Liu VW, Leung TH, Cheung AN and Ngan HY: Increased expression of PITX2 transcription factor contributes to ovarian cancer progression. PLoS One. 7:e370762012. View Article : Google Scholar : PubMed/NCBI
6	Ishibashi M, Nakayama K, Yeasmin S, et al: A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for taxol resistance in ovarian cancer. Clin Cancer Res. 14:3149–3155. 2008. View Article : Google Scholar : PubMed/NCBI
7	Rajkumar T, Soumittra N, Nancy NK, Swaminathan R, Sridevi V and Shanta V: BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in south india. Asian Pac J Cancer Prev. 4:203–208. 2003.PubMed/NCBI
8	Ghadersohi A, Odunsi K, Zhang S, et al: Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. Int J Cancer. 123:1376–1384. 2008. View Article : Google Scholar : PubMed/NCBI
9	Tassi RA, Calza S, Ravaggi A, et al: Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence. BMC Cancer. 9:2532009. View Article : Google Scholar : PubMed/NCBI
10	Rahman M, Nakayama K, Rahman M, et al: Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas. Brit J Cancer. 107:300–307. 2012. View Article : Google Scholar : PubMed/NCBI
11	Ng CK, Cooke SL, Howe K, et al: The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer. J Pathol. 226:703–712. 2012. View Article : Google Scholar
12	Ahmed AA, Mills AD, Ibrahim AE, et al: The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell. 12:514–527. 2007. View Article : Google Scholar : PubMed/NCBI
13	Krueger F, Kreck B, Franke A and Andrews SR: DNA methylome analysis using short bisulfite sequencing data. Nat Methods. 9:145–151. 2012. View Article : Google Scholar : PubMed/NCBI
14	Madougou S, Santcroos M, Benabdelkader A, et al: Provenance for distributed biomedical workflow execution. Stud Health Technol Inform. 175:91–100. 2012.PubMed/NCBI
15	Mao X, Cai T, Olyarchuk JG and Wei L: Automated genome annotation and pathway identification using the KEGG orthology (KO) as a controlled vocabulary. Bioinformatics. 21:3787–3793. 2005. View Article : Google Scholar : PubMed/NCBI
16	Langmead B, Trapnell C, Pop M and Salzberg SL: Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10:R252009. View Article : Google Scholar : PubMed/NCBI
17	Mortazavi A, Williams BA, Mccue K, Schaeffer L and Wold B: Mapping and quantifying mammalian transcriptomes by RNA-seq. Nat Methods. 5:621–628. 2008. View Article : Google Scholar : PubMed/NCBI
18	Audic S and Claverie JM: The significance of digital gene expression profiles. Genome Res. 7:986–995. 1997.PubMed/NCBI
19	Benjamini Y and Yekutieli D: The control of the false discovery rate in multiple testing under dependency. Ann Stat. 29:1165–1188. 2001.
20	Harr B and Schlötterer C: Comparison of algorithms for the analysis of affymetrix microarray data as evaluated by co-expression of genes in known operons. Nucleic Acids Res. 34:e82006. View Article : Google Scholar : PubMed/NCBI
21	Adamidi C, Wang Y, Gruen D, et al: De novo assembly and validation of planaria transcriptome by massive parallel sequencing and shotgun proteomics. Genome Res. 21:1193–1200. 2011. View Article : Google Scholar : PubMed/NCBI
22	Virtakoivu R, Pellinen T, Rantala JK, Perälä M and Ivaska J: Distinct roles of AKT isoforms in regulating β1-integrin activity, migration and invasion in prostate cancer. Mol Biol Cell. 23:3357–3369. 2012. View Article : Google Scholar : PubMed/NCBI
23	Dobashi Y, Kimura M, Matsubara H, Endo S, Inazawa J and Ooi A: Molecular alterations in AKT and its protein activation in human lung carcinomas. Hum Pathol. 43:2229–2240. 2012. View Article : Google Scholar : PubMed/NCBI
24	Bellacosa A, De Feo D, Godwin AK, et al: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 64:280–285. 1995. View Article : Google Scholar : PubMed/NCBI
25	Altomare DA, Wang HQ, Skele KL, et al: AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 23:5853–5857. 2004. View Article : Google Scholar : PubMed/NCBI
26	Chu CM: Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroen Hepatol. 15:E25–E30. 2000. View Article : Google Scholar
27	Parsonnet J, Friedman GD, Vandersteen DP, et al: Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 325:1127–1131. 1991. View Article : Google Scholar : PubMed/NCBI
28	Sobhani I, Walker F, Roudot-Thoraval F, et al: Anal carcinoma: incidence and effect of cumulative infections. Aids. 18:1561–1569. 2004. View Article : Google Scholar : PubMed/NCBI
29	Dreesen O and Brivanlou AH: Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev. 3:7–17. 2007. View Article : Google Scholar : PubMed/NCBI
30	Osman I, Drobnjak M, Fazzari M, et al: Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res. 5:2082–2088. 1999.PubMed/NCBI
31	Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al: Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 23:675–680. 2009. View Article : Google Scholar : PubMed/NCBI
32	Ho SM: Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol. 1:732003. View Article : Google Scholar : PubMed/NCBI
33	Pópulo H, Lopes JM and Soares P: The mTOR signalling pathway in human cancer. Int J Mol Sci. 13:1886–1918. 2012. View Article : Google Scholar : PubMed/NCBI
34	Guerrero K, Wang Z, Bachvarova M, et al: A novel genome-based approach correlates TMPRSS3 overexpression in ovarian cancer with DNA hypomethylation. Gynecol Oncol. 125:720–726. 2012. View Article : Google Scholar : PubMed/NCBI
35	Byrne J, Maleki S, Hardy JR, et al: MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC cancer. 10:4972010. View Article : Google Scholar : PubMed/NCBI
36	Guo Y, Fu P, Zhu H, et al: Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer. Oncol Rep. 27:286–292. 2012.
37	Hwang JR, Jo K, Lee Y, Sung BJ, Park YW and Lee JH: Upregulation of CD9 in ovarian cancer is related to the induction of TNF-α gene expression and constitutive NF-κB activation. Carcinogenesis. 33:77–83. 2012. View Article : Google Scholar
38	Seiz L, Dorn J, Kotzsch M, et al: Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. Biol Chem. 393:391–401. 2012. View Article : Google Scholar : PubMed/NCBI
39	Bock AJ, Nymoen DA, Brenne K, Kærn J and Davidson B: SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions. Hum Pathol. 43:669–674. 2012. View Article : Google Scholar
40	Chuan Y, Pang ST, Bergh A, Norstedt G and Pousette A: Androgens induce CD-9 in human prostate tissue. Int J Androl. 28:291–296. 2005. View Article : Google Scholar : PubMed/NCBI
41	Cook GA, Wilkinson DA, Crossno JT Jr, Raghow R and Jennings LK: The tetraspanin CD9 influences the adhesion, spreading and pericellular fibronectin matrix assembly of chinese hamster ovary cells on human plasma fibronectin. Exp Cell Res. 251:356–371. 1999. View Article : Google Scholar : PubMed/NCBI
42	Furuya M, Kato H, Nishimura N, et al: Down-regulation of CD9 in human ovarian carcinoma cell might contribute to peritoneal dissemination: morphologic alteration and reduced expression of β1 integrin subsets. Cancer Res. 65:2617–2625. 2005. View Article : Google Scholar : PubMed/NCBI
43	Notaridou M, Quaye L, Dafou D, et al: Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Int J Cancer. 128:2063–2074. 2011. View Article : Google Scholar :
44	Acampora D, D’esposito M, Faiella A, et al: The human hox gene family. Nucleic Acids Res. 17:10385–10402. 1989. View Article : Google Scholar : PubMed/NCBI
45	Ota T, Klausen C, Salamanca MC, Woo HL, Leung PC and Auersperg N: Expression and function of HOXA genes in normal and neoplastic ovarian epithelial cells. Differentiation. 77:162–171. 2009. View Article : Google Scholar : PubMed/NCBI
46	Gendronneau G, Boucherat O, Aubin J, Lemieux M and Jeannotte L: The loss of Hoxa5 function causes estrous acyclicity and ovarian epithelial inclusion cysts. Endocrinology. 153:1484–1497. 2012. View Article : Google Scholar : PubMed/NCBI
47	Morgan R, Plowright L, Harrington KJ, Michael A and Pandha HS: Targeting HOX and PBX transcription factors in ovarian cancer. BMC cancer. 10:892010. View Article : Google Scholar : PubMed/NCBI